Physician profile
Jeffrey C Bedrosian
NPI 1821252974
$727,496.29
in general payments reported to CMS, 2019-2025
32 companies · $247K in 2025
The $247K reported for 2025 was more than what 99% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66K · 2020: $34K · 2021: $31K · 2022: $87K · 2023: $81K · 2024: $181K · 2025: $247K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $412K · Travel and Lodging: $55K · Consulting Fee: $25K · Food and Beverage: $17K · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $411,728.50 |
| Travel and Lodging | $54,552.27 |
| Consulting Fee | $24,789.00 |
| Food and Beverage | $17,220.48 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $338,569.20 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $120,932.04 | 2021-2025 | Dupixent |
| Genzyme Corporation | $99,041.62 | 2019-2025 | |
| Glaxosmithkline, LLC. | $94,531.55 | 2021-2025 | Nucala |
| Medical Device Business Services, INC. | $43,445.88 | 2019-2023 | |
| Neurent Medical Limited | $22,645.82 | 2022-2025 | Neuromark Radiofrequency Console, Neuromark Device, Neuromark System |
| Acclarent, INC | $4,798.53 | 2019-2023 | Acclarent Balloon Inflation Device, Trudi Nav Cable, Trudi Nav Suction |
| Medtronic, INC. | $1,152.20 | 2021-2025 | Propel, Nim-Response, Pteye Parathyroid Detection System |
| Aerin Medical INC. | $530.73 | 2022-2025 | |
| Intersect Ent, INC. | $431.40 | 2019-2022 | |
| Stryker Corporation | $286.59 | 2019-2025 | Scopis Ent |
| 3-D Matrix, INC. | $264.53 | 2024 | |
| Organogenesis INC. | $180.59 | 2022-2025 | Puraply, Affinity |
| Pfizer INC. | $104.10 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $88.88 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $88.25 | 2023-2024 | Dupixent |
| Medtronic USA, INC. | $60.53 | 2019 | |
| Paratek Pharmaceuticals, INC. | $49.00 | 2025 | Xhance |
| Merck Sharp & Dohme LLC | $44.94 | 2021-2025 | Keytruda |
| Amgen INC. | $34.00 | 2025 | |
| Hologic Sales and Service, LLC | $28.69 | 2023-2024 | Coolseal Generator |
| Alk-Abello, INC | $28.62 | 2019-2020 | |
| Axogen | $22.09 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $19.95 | 2021 | |
| Cook Medical LLC | $19.04 | 2019 | |
| Omeros Corporation | $18.00 | 2019 | |
| Integra Lifesciences Corporation | $17.04 | 2024 | Acclarent Aera |
| Astrazeneca Pharmaceuticals Lp | $14.00 | 2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $13.95 | 2019 | |
| Covidien Lp | $13.64 | 2019 | |
| Atos Medical INC | $11.33 | 2019 | |
| Phathom Pharmaceuticals, INC. | $9.56 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Bedrosian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.